Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer.
Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Mittendorf EA, et al. Among authors: storrer ce. Ann Surg Oncol. 2006 Aug;13(8):1085-98. doi: 10.1245/ASO.2006.03.069. Epub 2006 Jul 24. Ann Surg Oncol. 2006. PMID: 16865596 Clinical Trial.
Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Amin A, Benavides LC, Holmes JP, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Storrer CE, Jama YH, Craig D, Stojadinovic A, Ponniah S, Peoples GE. Amin A, et al. Among authors: storrer ce. Cancer Immunol Immunother. 2008 Dec;57(12):1817-25. doi: 10.1007/s00262-008-0509-2. Epub 2008 Apr 8. Cancer Immunol Immunother. 2008. PMID: 18392824 Clinical Trial.
Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, Storrer CE, Craig D, Ioannides CG, Ponniah S. Peoples GE, et al. Among authors: storrer ce. Clin Cancer Res. 2008 Feb 1;14(3):797-803. doi: 10.1158/1078-0432.CCR-07-1448. Clin Cancer Res. 2008. PMID: 18245541 Free article. Clinical Trial.
Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology.
Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Shriver CD, Ponniah S, Peoples GE. Dehqanzada ZA, et al. Among authors: storrer ce. Oncol Rep. 2007 Mar;17(3):687-94. Oncol Rep. 2007. PMID: 17273752 Clinical Trial.
Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine.
Hueman MT, Stojadinovic A, Storrer CE, Dehqanzada ZA, Gurney JM, Shriver CD, Ponniah S, Peoples GE. Hueman MT, et al. Among authors: storrer ce. Cancer Immunol Immunother. 2007 Feb;56(2):135-46. doi: 10.1007/s00262-006-0188-9. Epub 2006 Jun 17. Cancer Immunol Immunother. 2007. PMID: 16783576 Clinical Trial.
Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.
Hueman MT, Stojadinovic A, Storrer CE, Foley RJ, Gurney JM, Shriver CD, Ponniah S, Peoples GE. Hueman MT, et al. Among authors: storrer ce. Breast Cancer Res Treat. 2006 Jul;98(1):17-29. doi: 10.1007/s10549-005-9108-5. Epub 2006 Jun 7. Breast Cancer Res Treat. 2006. PMID: 16758122
Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
Mittendorf EA, Storrer CE, Foley RJ, Harris K, Jama Y, Shriver CD, Ponniah S, Peoples GE. Mittendorf EA, et al. Among authors: storrer ce. Cancer. 2006 Jun 1;106(11):2309-17. doi: 10.1002/cncr.21849. Cancer. 2006. PMID: 16596621 Free article. Clinical Trial.
Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer.
Mittendorf EA, Gurney JM, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Mittendorf EA, et al. Among authors: storrer ce. Surgery. 2006 Mar;139(3):407-18. doi: 10.1016/j.surg.2005.06.059. Surgery. 2006. PMID: 16546506
Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients.
Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Kao TC, Shriver CD, Ponniah S, Peoples GE. Dehqanzada ZA, et al. Among authors: storrer ce. Clin Cancer Res. 2006 Jan 15;12(2):478-86. doi: 10.1158/1078-0432.CCR-05-1425. Clin Cancer Res. 2006. PMID: 16428490 Free article.
Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
Hueman MT, Dehqanzada ZA, Novak TE, Gurney JM, Woll MM, Ryan GB, Storrer CE, Fisher C, McLeod DG, Ioannides CG, Ponniah S, Peoples GE. Hueman MT, et al. Among authors: storrer ce. Clin Cancer Res. 2005 Oct 15;11(20):7470-9. doi: 10.1158/1078-0432.CCR-05-0235. Clin Cancer Res. 2005. PMID: 16243821 Free article. Clinical Trial.
16 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback